From the water-soluble portion of the methanol extract of stems of Ficus tikoua Bur., a new benzofuran glucoside, named 6-carboxyethyl-5-hydroxybenzofuran 5-O-β-d-glucopyranoside (1), together with one known benzofuran glucoside (2) were isolated. Their structures were elucidated by 1D and 2D ((1)H-(1)H COSY, HMQC, and HMBC) NMR spectroscopy and HRMS techniques. The antioxidant activities of the isolated compounds were assayed based on the scavenging activities of DPPH free radical. Compounds 1 and 2 exhibited moderate antioxidant activities, and the IC(50) values were 242.8 μg·mL(-1) and 324.9 μg·mL(-1), respectively.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179143 | PMC |
| http://dx.doi.org/10.3390/ijms12084946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics of the material basis compounds of Tianshu capsule in treating migraine.
J Ethnopharmacol
February 2025
State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Jiangsu Kanion Pharmaceutical Co., Ltd, Lianyungang, 222001, China; Jiangsu Kanion Pharmaceutical Co., Ltd., Nanjing, 211100, China; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. Electronic address:
Article Synopsis
- Tianshu capsule (TSC) is a traditional Chinese medicine that shows promise in treating migraines, prompting a study to explore its compound effects and pharmacokinetics.
- The research utilized advanced chromatography techniques to identify 46 compounds in blood and brain of rats after TSC administration, highlighting four key ingredients (Gastrodin, ferulic acid, senkyunolide G, and senkyunolide I).
- Findings revealed that these compounds, especially senkyunolide I, quickly reached the brain and showed differences in absorption between healthy and migraine-affected rats, indicating a need for deeper investigation into TSC's therapeutic mechanisms.
Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.
Diabetes Obes Metab
October 2024
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Aims: To evaluate the long-term safety and efficacy of enavogliflozin monotherapy (0.3 mg/day) in individuals with type 2 diabetes mellitus (T2DM).
Materials And Methods: Following a 24-week randomized, double-blind treatment period with enavogliflozin 0.
RP-UHPLC-ESI-QTOF-MS analyses and evaluation of the antioxidant, antimicrobial, anti-diabetic and anti-Alzheimer activities of Desf.
Nat Prod Res
July 2024
Université Constantine 1-frères Mentouri, Laboratoire d'Obtention de Substances Thérapeutiques (LOST), Constantine, Algeria.
The polyphenolic compounds of the -butanol fraction of Desf. (BFLTe) were characterised by RP-UHPLC-ESI-QTOF-MS analyses with the main presence of 6,8-di--glucosyl naringenin (11.7%), vicenin 2-isomer 2 (8.
View Article and Find Full Text PDFThe effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
Diabetes Obes Metab
July 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea.
Aims: To explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM).
Methods: An open-label, two-part clinical trial was conducted in T2DM patients, stratified by renal function: Group 1, normal renal function; Group 2, mild renal impairment (RI); Group 3, moderate RI; and Group 4, severe RI. In Part A, Groups 2 and 4 received enavogliflozin 0.
A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
Diabetes Obes Metab
June 2024
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Aim: To evaluate the long-term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin in patients with type 2 diabetes mellitus.
Materials And Methods: After 24 weeks of a randomized, double-blind treatment period with enavogliflozin 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!